Relating to medication-assisted treatment programs
SB726 would amend West Virginia’s Medication-Assisted Treatment Program Licensing Act by creating a new section that requires licensed or registered medication-assisted treatment (MAT) centers and entities to convert to an “integrated-care model” by July 1, 2026. The bill defines that model as onsite, in-person care delivered by regulated health professionals and combining addiction treatment with counseling, recovery services, and broader medical services. The required services include routine screenings, HIV/hepatitis/STI testing, birth control and long-acting reversible contraceptives, vaccinations, basic diagnostics, treatment for common minor illnesses and injuries, and overdose prevention supplies and education.
The bill also requires MAT programs to expand the services they offer to include advanced diagnostics, behavioral health services, chronic disease management, and health education and counseling such as nutrition and weight management. It further requires informed consent at program entry and at least quarterly thereafter, with updated consent whenever treatment changes, and requires periodic quarterly assessments of each client’s physical, mental, and psychosocial status. The informed consent must be provided by a chapter 30-trained medical professional. A limited exemption is created for certain buprenorphine-prescribing programs that provide behavioral telehealth services and follow ASAM guidelines, though those programs must still comply with the informed-consent and assessment provisions and refer patients to primary care every three months during continuous treatment.
The bill directs the Office of the Inspector General, in consultation with the Office of Drug Control Policy, to propose emergency rules to define qualified professionals and implement the new requirements. It also requires a report to the Legislative Oversight Commission on Health and Human Resources Accountability by December 15, 2025, on telehealth findings. In practical terms, the bill would expand the regulatory obligations of MAT providers and likely increase the scope of services, staffing, documentation, and compliance requirements for opioid treatment and office-based medication-assisted treatment programs.
The overall sentiment reflected in the available legislative history is strongly supportive: the Senate passed the bill 32-0. No committee transcript excerpts were provided, so there is no recorded floor or committee debate in the supplied materials. The unanimous vote suggests broad agreement on the goal of improving treatment quality and access, especially by pairing addiction treatment with primary care and preventive health services.
The main points of potential contention are the mandate to convert all MAT programs to an integrated-care model and the operational burden that may place on providers, especially smaller or telehealth-oriented programs. The bill’s exemption for certain buprenorphine and telehealth providers indicates an effort to accommodate existing treatment models, but it still preserves several new requirements and a referral obligation to primary care. Another likely issue is the rulemaking authority given to the Inspector General and the need to define which professionals may provide the required services.
SB726 would add a new section to the West Virginia Code governing medication-assisted treatment programs, imposing new service, consent, assessment, reporting, and rulemaking requirements on MAT centers and office-based treatment entities licensed or registered under §§16B-13-3 and 16B-13-4. It would effectively expand the minimum scope of care these providers must offer, require quarterly informed consent and client reassessment, and authorize emergency rules to implement the new standards. The bill also creates a limited exemption for certain buprenorphine and telehealth-based providers, while preserving core informed-consent and monitoring duties.
The available voting history shows strong bipartisan or at least unanimous support in the Senate, with passage by a 32-0 vote. No committee testimony or debate excerpts were provided, so the broader discussion record is limited. Based on the vote, the bill appears to have been viewed favorably as a patient-care and treatment-quality measure rather than a controversial policy change.
The likely areas of contention are the bill’s broad mandate that all MAT programs convert to an integrated-care model by a fixed date, the added staffing and compliance costs, and the extent to which telehealth-oriented or buprenorphine-focused providers should be exempt. Providers may also question the requirement that informed consent be delivered by a chapter 30-trained medical professional and the practical feasibility of offering the full range of onsite services, including screenings, vaccinations, diagnostics, and primary-care-style treatment. The bill’s supporters appear to favor a more comprehensive, coordinated treatment model, while any opposition would likely come from providers concerned about implementation burden and regulatory flexibility.